Main Content

Search loading...

Press Release

Clarity 3D Ultrasound Innovation Offers Remote Automatic Scanning to Guide Prostate Cancer Radiation Therapy

ATLANTA, GA

2012-02-20

Elekta receives FDA 510(k) clearance for Clarity with Autoscan radiotherapy imaging solution


Clarity® soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient’s perineum. The transperineal approach also benefits planning by providing a clear view of the prostate and surrounding critical areas, such as the penile bulb, thought to be responsible for erectile function. Clearly visualizing these pelvic structures could enable physicians to create plans with tighter margins around intended targets, thus avoiding exposure to uninvolved tissues, including the penile bulb.

Elekta recently received 510(k) clearance for Clarity with Autoscan, enabling U.S. medical centers to implement this new ultrasound scanning innovation.

Clarity with Autoscan provides a flexible alternative to traditional hand-held scanning and is the ideal platform on which to build future live (i.e., real time) imaging applications that will track the prostate and surrounding anatomy during treatment*. Live imaging has become increasingly important for physicians wanting to pursue reduced margin hypofractionated therapy. Clarity with Autoscan, as well as live-imaging works-in-progress, will be part of the Elekta product portfolio highlighted at the Radiosurgery Society meeting in Carlsbad, Calif., February 23-25.

Clinicians at Fletcher Allen Health Care (FAHC, Burlington, Vt.) who have been evaluating Clarity with Autoscan in clinical trials are excited about Elekta’s latest innovation for soft-tissue imaging in radiation therapy.

“In our experience, patients have found transperineal scanning to be more comfortable than transabdominal ultrasound, because it doesn’t require pressing the ultrasound probe on a full bladder,” says FAHC radiation oncologist James Wallace, M.D. “The images we acquire truly are remarkable and the therapists say setup is very user-friendly. In addition, we are excited to begin assessing the impact of real-time Autoscan, which will enable us to use Clarity to track prostate motion in real-time during treatment, facilitating ‘on-the-fly’ adjustments to patient position.”

To learn more, visit www.elekta.com/clarity.

*Works in progress and not available for sale or distribution.

 

###

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: stina.thorman@elekta.com
Time zone: CET: Central European Time
 
Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time
 
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

Your Feedback:


Send message Close window